Search results
Groundbreaking Robotics Curing Adrenal Problems
WILX 10 Lansing· 1 day agoA groundbreaking single-incision adrenal surgery is brand new and it’s proving to be much faster, resulting in shorter hospital stays. Adrenal problems...
BridgeBio spinout launches with $200M for KRAS cancer drugs
BioPharma Dive via Yahoo Finance· 3 days agoMuting this signaling should help slow tumor growth, as PI3Ka mutations are found in many types of ...
Edison Oncology's Orotecan®: A Brighter Future For The Treatment of Recurrent Pediatric Cancers
International Business Times· 6 days agoDiagnosis of pediatric cancer is one of the worst news a family can receive. Having a young family member with cancer affects the entire family's dynamics ...
Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates
Zacks· 3 days agoCorcept (CORT) beats on both earnings and sales in the first quarter of 2024. The company increases revenue guidance for 2024.
Earnings call: Corcept Therapeutics raises 2024 revenue guidance
Investing.com· 3 days agoThe company has also raised its revenue guidance for the full year to between $620 million and $650...
What are the real benefits of intermittent fasting?
The Telegraph via Yahoo News· 2 days agoIt’s not just the fat-burning benefits that make intermittent fasting so popular. Hailed for boosting our “metabolic resilience”, studies show that...
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 days agoCorcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript May 1, 2024 Corcept...
Cytokine Release Syndrome: What to Know
Verywell Health via Yahoo News· 2 days agoCytokine release syndrome (CRS) occurs when the immune system responds to infection or immunotherapy drugs more aggressively than it should. Learn more...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Average Rating of “Moderate Buy” from Brokerages
ETF DAILY NEWS· 4 days agoShares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the company, MarketBeat ...